시장보고서

상품코드

1584128

세계의 털세포 백혈병 치료 시장 : 약제 클래스별, 치료 유형별, 투여 경로별, 최종 사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예상(2024-2032년)

Hairy Cell Leukemia Treatment Market, By Drug Class, By Therapy Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 10월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 269 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

털세포 백혈병 치료 시장 규모는 2023년에 1억 290만 달러로 2024년부터 2032년까지 연평균 복합 성장률(CAGR) 5.40%로 확대

털세포 백혈병 치료 시장 - 시장 역학

인지도 향상과 조기 진단은 유모 세포 백혈병 치료 시장의 성장을 가속

조기 발견에 의해 환자의 5년 생존율이 90% 이상이 되는 것을 나타내는 미국암 협회의 보고서가 강조하고 있는 것처럼, 인지도의 향상과 조기 진단이 털세포 백혈병 치료 시장의 성장을 크게 밀어줍니다. 백혈병 림프종 협회(Leukemia & Lymphoma Society) 등의 건강 관리 단체는 유모 세포 백혈병의 증상과 적시 진단의 중요성에 대한 이해를 깊게하기 위해 의료 종사자와 일반 시민 모두를 대상으로 한 교육 캠페인을 시작했습니다. 이니셔티브는 스크리닝을 수행하고 전문 의료에 대한 접근성을 개선하여 보다 초기 단계에서 환자를 쉽게 식별할 수 있게 했습니다. 게다가, 클라드리빈과 같은 표적 치료제를 포함한 새로운 치료 옵션이 이용 가능하게 됨으로써, 보다 조기의 개입이 촉진되고 있습니다. 환자의 결과를 개선하고 이 희귀한 암의 전반적인 치료 상황을 개선하기 위해서는 인식과 조기 진단에 초점을 맞추는 것이 중요합니다.

털세포 백혈병 치료 시장 - 주요 인사이트

우리의 리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2024-2032년)에 CAGR 약 5.40%로 매년 성장할 것으로 추정됩니다.

약물 등급별로는, 퓨린 유사체가 2023년에 가장 큰 시장 점유율을 보여줄 것으로 예상됐습니다.

치료 유형별로는 화학요법이 2023년 주요 유형이었습니다.

투여 경로별로는 정맥내 투여가 2023년의 주요 유형이었습니다.

지역별로는 북미가 2023년의 수익으로 최고였습니다.

털세포 백혈병 치료 시장 - 세분화 분석 :

세계의 털세포 백혈병 치료 시장은 약물 클래스별, 치료 유형별, 투여 경로별, 최종 사용자별, 지역별로 구분됩니다.

약물 클래스별로, 퓨린 유사체, BRAF 억제제, CD20 단클론항체의 세 가지 범주로 나뉩니다. CD20 단일 클론 항체도 효과적이지만 일반적으로 병용 요법에 사용됩니다.

치료 유형별로는 화학요법, 표적요법, 면역요법, 병용요법의 4가지 범주로 나뉩니다. BRAF와 같은 특정 유전자 변이에 초점을 맞춘 표적 요법이 이어집니다.

털세포 백혈병 치료 시장 - 지리적 통찰

북미는 털세포 백혈병 치료 시장의 주요 지역이며, 고급 의료 인프라와 연구 개발에 많은 투자가 견인하고 있습니다. 관련 특정 돌연변이를 표적으로 하는 새로운 치료 승인 그리고 환자의 치료 옵션을 강화했습니다. 또한 미국 암 협회는 미국의 조기 진단 노력이 생존율의 개선으로 이어졌다고 보고하고, 이 지역 시장에서의 우위성에 기여하고 있습니다 유럽에서는 독일과 영국 등의 국가들이 환자의 예후 개선에 유망한 표적 면역요법을 포함한 신규 요법에 초점을 맞춘 임상시험으로 약진하고 있습니다. 생명 공학 기업과 주요 암 연구 센터와의 제휴는 털세포 백혈병의 맞춤형 치료 계획의 개발을 촉진하는 것을 목적으로 하고 있습니다. 드문 암에 대한 보다 견고한 치료 상황이 형성되고 있습니다.

털세포 백혈병 치료 시장 - 경쟁 구도:

털세포 백혈병 치료 시장 경쟁 구도은 Novartis사나 Teva Pharmaceuticals사 등의 기업이 치료 개발로 크게 전진하고 있는 북미가 주로 견인하고 있습니다. 환자의 컴플라이언스와 치료 성적 향상을 목표로 했습니다. 혈병 림프종 협회와의 파트너십은 충분한 치료를 받지 않은 사람들의 인지도를 높이고 치료 접근을 개선하는 데 중점을 둡니다. 한 신규 표적 치료제의 임상시험을 실시하여 포트폴리오의 확충을 도모하고 있습니다. Sciences의 Kite Pharma 인수는 유모 세포 백혈병에 적응할 수있는 세포 요법에 중점을두고 혈액 악성 종양 분야의 입지를 강화했습니다. 앞으로 나아가기 위해서는 협력과 혁신이 핵심적인 역동적이고 경쟁적인 환경을 반영합니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 털세포 백혈병 치료 업계

경쟁 대시보드
기업 프로파일
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Johnson &Johnson
- Merck &Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Others

제13장 애널리스트의 전방위 전망

JHS 24.11.29

REPORT HIGHLIGHT

Hairy Cell Leukemia Treatment Market size was valued at USD 102.90 Million in 2023, expanding at a CAGR of 5.40% from 2024 to 2032.

The Hairy Cell Leukemia Treatment Market focuses on therapies for hairy cell leukemia (HCL), a rare type of blood cancer characterized by the overproduction of abnormal B lymphocytes. It accounts for approximately 2% of all leukemia cases, making targeted treatment options critical for affected patients. Increased awareness and early diagnosis are contributing to market growth, with organizations like the Leukemia & Lymphoma Society reporting a significant rise in new treatment modalities that improve patient outcomes. However, the market faces challenges, including the limited number of available treatment options and high costs associated with newer therapies, which may restrict access for some patients. Additionally, the rarity of the disease can lead to difficulties in recruitment for clinical trials, impacting research and development. Opportunities exist in the development of novel therapies, such as targeted agents and immunotherapies, which show promise in improving treatment efficacy. Furthermore, ongoing research into the molecular mechanisms of HCL presents avenues for innovative treatment strategies that could enhance patient quality of life and outcomes.

Hairy Cell Leukemia Treatment Market- Market Dynamics

Increased Awareness and Early Diagnosis Fuel Growth in the Hairy Cell Leukemia Treatment Market

Increased awareness and early diagnosis are significantly fueling growth in the Hairy Cell Leukemia Treatment Market, as highlighted by the American Cancer Society's reports indicating that early detection can lead to a more than 90% five-year survival rate for patients. Advocacy groups such as the Leukemia & Lymphoma Society have launched educational campaigns aimed at both healthcare professionals and the public to enhance understanding of hairy cell leukemia symptoms and the importance of timely diagnosis. These initiatives have resulted in improved screening practices and access to specialized care, facilitating the identification of patients at earlier stages of the disease. Additionally, the availability of newer treatment options, including targeted therapies like cladribine, is encouraging earlier intervention. With an estimated incidence rate of about 3,000 new cases of hairy cell leukemia diagnosed annually in the United States, the focus on awareness and early diagnosis is critical in improving patient outcomes and enhancing the overall treatment landscape for this rare cancer.

Hairy Cell Leukemia Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.40% over the forecast period (2024-2032)

Based on Drug Class segmentation, Purine Analogues was predicted to show maximum market share in the year 2023

Based on Therapy Type segmentation, Chemotherapy was the leading type in 2023

Based on Route of Administration segmentation, Intravenous (IV) administration was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Hairy Cell Leukemia Treatment Market- Segmentation Analysis:

The Global Hairy Cell Leukemia Treatment Market is segmented on the basis of Drug Class, Therapy Type, Route of Administration, End-User, and Region.

The market is divided into three categories based on Drug Class: Purine Analogues, BRAF Inhibitors, and CD20 Monoclonal Antibodies. Purine analogs hold the highest priority due to their established efficacy in treating hairy cell leukemia, particularly cladribine. BRAF inhibitors follow, targeting specific mutations in some patients, while CD20 monoclonal antibodies are also effective but are generally used in combination therapies.

The market is divided into four categories based on Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Combination Therapy. Purine Analogues, BRAF Inhibitors, and CD20 Monoclonal Antibodies. Chemotherapy remains the highest priority therapy for hairy cell leukemia, particularly with drugs like cladribine being the standard of care. Targeted therapy follows, focusing on specific genetic mutations such as BRAF. Immunotherapy is emerging but less common, while combination therapy is increasingly used for resistant cases.

Hairy Cell Leukemia Treatment Market- Geographical Insights

North America is the leading region in the Hairy Cell Leukemia Treatment Market, driven by advanced healthcare infrastructure and significant investments in research and development. In 2023, the U.S. Food and Drug Administration (FDA) approved a new therapy, targeting specific mutations associated with hairy cell leukemia, enhancing treatment options for patients. The American Cancer Society has also reported that early diagnosis initiatives in the U.S. have led to improved survival rates, contributing to the region's prominence in the market. In Europe, countries like Germany and the UK are making strides with clinical trials focusing on novel therapies, including targeted immunotherapies, which have shown promise in improving patient outcomes. Collaborative efforts between pharmaceutical companies and research institutions in these regions are fostering innovation; for instance, a partnership between a biotech firm and a major cancer research center aims to expedite the development of personalized treatment plans for hairy cell leukemia. As awareness increases globally, access to cutting-edge therapies continues to improve, shaping a more robust treatment landscape for this rare cancer.

Hairy Cell Leukemia Treatment Market- Competitive Landscape:

The competitive landscape of the Hairy Cell Leukemia Treatment Market is primarily led by North America, where companies like Novartis and Teva Pharmaceuticals are making significant strides in therapy development. In 2023, Novartis announced the launch of a new formulation of cladribine, a well-established treatment for hairy cell leukemia, aimed at enhancing patient compliance and treatment outcomes. In addition, the partnership between Teva and the Leukemia & Lymphoma Society has focused on increasing awareness and improving access to treatment for underserved populations. Meanwhile, in Europe, Roche has been expanding its portfolio with ongoing clinical trials for novel targeted therapies that aim to enhance treatment efficacy. The acquisition of Kite Pharma by Gilead Sciences has also fortified its position in the hematologic malignancies sector, focusing on cell therapies that could be adapted for hairy cell leukemia. These developments reflect a dynamic and competitive environment where collaboration and innovation are key to advancing treatment options for patients with this rare form of leukemia.

Recent Developments:

In August 2022, the U.S. FDA approved AstraZeneca's tablet formulation of Calquence for treating small lymphocytic leukemia (SLL), chronic lymphocytic leukemia (CLL), and relapsed or refractory mantle cell lymphoma (MCL), enhancing the company's product portfolio and market presence.

In September 2018, the FDA approved AstraZeneca's Lumoxiti injection for treating adult patients with relapsed or refractory hairy cell leukemia (HCL) who had undergone at least two prior systemic therapies, enhancing the company's product offerings and increasing revenue potential.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HAIRY CELL LEUKEMIA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche AG
Gilead Sciences, Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Others

GLOBAL HAIRY CELL LEUKEMIA TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Purine Analogues
BRAF Inhibitors
CD20 Monoclonal Antibodies

GLOBAL HAIRY CELL LEUKEMIA TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

Chemotherapy
Targeted Therapy
Immunotherapy
Combination Therapy

GLOBAL HAIRY CELL LEUKEMIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Intravenous

GLOBAL HAIRY CELL LEUKEMIA TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Oncology Clinics
Research Institutions

GLOBAL HAIRY CELL LEUKEMIA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Hairy Cell Leukemia Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Hairy Cell Leukemia Treatment Market Snippet by Drug Class
- 2.1.2. Hairy Cell Leukemia Treatment Market Snippet by Therapy Type
- 2.1.3. Hairy Cell Leukemia Treatment Market Snippet by Route of Administration
- 2.1.4. Hairy Cell Leukemia Treatment Market Snippet by End-User
- 2.1.5. Hairy Cell Leukemia Treatment Market Snippet by Country
- 2.1.6. Hairy Cell Leukemia Treatment Market Snippet by Region
2.2. Competitive Insights

3. Hairy Cell Leukemia Treatment Key Market Trends

3.1. Hairy Cell Leukemia Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Hairy Cell Leukemia Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Hairy Cell Leukemia Treatment Market Opportunities
3.4. Hairy Cell Leukemia Treatment Market Future Trends

4. Hairy Cell Leukemia Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Hairy Cell Leukemia Treatment Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Hairy Cell Leukemia Treatment Market Landscape

6.1. Hairy Cell Leukemia Treatment Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Hairy Cell Leukemia Treatment Market - By Drug Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 7.1.2. Purine Analogues
- 7.1.3. BRAF Inhibitors
- 7.1.4. CD20 Monoclonal Antibodies

8. Hairy Cell Leukemia Treatment Market - By Therapy Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
- 8.1.2. Chemotherapy
- 8.1.3. Targeted Therapy
- 8.1.4. Immunotherapy
- 8.1.5. Combination Therapy

9. Hairy Cell Leukemia Treatment Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Intravenous

10. Hairy Cell Leukemia Treatment Market - By End-User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Oncology Clinics
- 10.1.4. Research Institutions

11. Hairy Cell Leukemia Treatment Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Hairy Cell Leukemia Treatment Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Hairy Cell Leukemia Treatment Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Hairy Cell Leukemia Treatment Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Hairy Cell Leukemia Treatment Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Hairy Cell Leukemia Treatment Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Hairy Cell Leukemia Treatment Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. AbbVie Inc.
- 12.2.2. Amgen Inc.
- 12.2.3. AstraZeneca PLC
- 12.2.4. Bayer AG
- 12.2.5. Bristol-Myers Squibb Company
- 12.2.6. Eli Lilly and Company
- 12.2.7. F. Hoffmann-La Roche AG
- 12.2.8. Gilead Sciences, Inc.
- 12.2.9. GlaxoSmithKline plc
- 12.2.10. Johnson & Johnson
- 12.2.11. Merck & Co., Inc.
- 12.2.12. Novartis AG
- 12.2.13. Pfizer Inc.
- 12.2.14. Sanofi S.A.
- 12.2.15. Takeda Pharmaceutical Company Limited
- 12.2.16. Teva Pharmaceutical Industries Ltd.
- 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us